The Technical AnalystExchange: EURONEXT Industry: Medical Devices
Theradiag SA Price, Forecast, Insider, Ratings, Fundamentals & Signals
-4.91% €1.260
America/New_York / 15 des 2023 @ 11:08
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 17.29 mill |
| EPS: | 0.0300 |
| P/E: | 42.00 |
| Earnings Date: | Oct 10, 2023 |
| SharesOutstanding: | 13.72 mill |
| Avg Daily Volume: | 0.0041 mill |
| RATING 2023-12-19 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Neutral | |
| P/E: | Buy | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 1/22 | 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | |
| Revenue | n/a | n/a | n/a | |||
| Gr.Profit | n/a | n/a | n/a | |||
| Ebit | n/a | n/a | n/a | |||
| Asset | n/a | n/a | n/a | |||
| Debt | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 2.38x |
| Company: PE 42.00 | sector: PE 17.68 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.70x |
| Company: PE 42.00 | industry: PE 60.12 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
€ 1.224 - 1.296 ( +/- 2.86%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | €1.260 (-4.91% ) |
| Volume | 0.0316 mill |
| Avg. Vol. | 0.0041 mill |
| % of Avg. Vol | 776.54 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ALTER.PA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ALTER.PA
Theradiag SA develops, manufactures, and markets in-vitro diagnostic products. It offers autoimmunity reagents; IMMUNO-TROL, a multi-parametric quality control tool; various instruments for autoimmunity and infectious diseases testing; SQA-V system, a semen analyzer; and V-Sperm for loading results, pictures, and videos of the samples into the computer. The company also provides instrumentation, including Theralis that integrates multiplex FIDIS immunofluorescence and ELISA; Theralis µ, a solution for medium sized laboratories; and FIDIS platform used in laboratory for analysis. In addition, it offers therapeutic drug monitoring services for treatment of chronic inflammatory diseases; and LISA tracker, a tool for monitoring of biotherapies, as well as Elisa and rapid tests for SARS-CoV 2 serology. The company was founded in 1986 and is based in Marne La Vallee, France.